Industry To Supreme Court: Investors Don't Need To See All Adverse Event Reports
This article was originally published in The Pink Sheet Daily
Executive Summary
In an amicus brief filed in the case of Matrixx v. Siracusano, regarding patients who reported losing their sense of smell after taking Zicam, AdvaMed argues companies could end up reporting individual adverse events if the Court doesn't reverse a 2009 appeals court decision.